Cargando…

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients

Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS)(1,2), but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation(3,4). To understan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cassotta, Antonino, Mikol, Vincent, Bertrand, Thomas, Pouzieux, Stéphanie, Le Parc, Josiane, Ferrari, Paul, Dumas, Jacques, Auer, Michael, Deisenhammer, Florian, Gastaldi, Matteo, Franciotta, Diego, Silacci-Fregni, Chiara, Fernandez Rodriguez, Blanca, Giacchetto-Sasselli, Isabella, Foglierini, Mathilde, Jarrossay, David, Geiger, Roger, Sallusto, Federica, Lanzavecchia, Antonio, Piccoli, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795539/ https://www.ncbi.nlm.nih.gov/pubmed/31501610 http://dx.doi.org/10.1038/s41591-019-0568-2

Ejemplares similares

Clonal composition and persistence of antigen‐specific circulating T follicular helper cells
por: Hu, Mengyun, et al.
Publicado: (2022)

Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts
por: Phad, Ganesh E., et al.
Publicado: (2022)

A LAIR-1 insertion generates broadly reactive antibodies against malaria variant antigens
por: Tan, Joshua, et al.
Publicado: (2015)

Structural basis of malaria RIFIN binding by LILRB1-containing antibodies
por: Chen, Yiwei, et al.
Publicado: (2021)

Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis
por: Piccoli, Luca, et al.
Publicado: (2015)

Deciphering and predicting CD4(+) T cell immunodominance of influenza virus hemagglutinin
por: Cassotta, Antonino, et al.
Publicado: (2020)

Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland
por: Piccoli, Luca, et al.
Publicado: (2020)

Public antibodies to malaria antigens generated by two LAIR1 insertion modalities
por: Pieper, Kathrin, et al.
Publicado: (2017)

Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
por: Low, Jun Siong, et al.
Publicado: (2021)

Somatic mutations and affinity maturation are impaired by excessive numbers of T follicular helper cells and restored by Treg cells or memory T cells
por: Preite, Silvia, et al.
Publicado: (2015)

Broadly reactive human CD4(+) T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire
por: Cassotta, Antonino, et al.
Publicado: (2020)

Chemokine Receptor Expression Identifies Pre–T Helper (Th)1, Pre–Th2, and Nonpolarized Cells among Human CD4(+) Central Memory T Cells
por: Rivino, Laura, et al.
Publicado: (2004)

A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein
por: Tan, Joshua, et al.
Publicado: (2018)

Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment
por: Castellazzi, Massimiliano, et al.
Publicado: (2015)

Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
por: Castellazzi, Massimiliano, et al.
Publicado: (2016)

AncesTree: An interactive immunoglobulin lineage tree visualizer
por: Foglierini, Mathilde, et al.
Publicado: (2020)

Human naive and memory CD4(+) T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells
por: Geiger, Rebekka, et al.
Publicado: (2009)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Phenotype and specificity of T cells in primary human cytomegalovirus infection during pregnancy: IL-7R(pos) long-term memory phenotype is associated with protection from vertical transmission
por: Mele, Federico, et al.
Publicado: (2017)

Mobilizing Dendritic Cells for Tolerance, Priming, and Chronic Inflammation
por: Sallusto, Federica, et al.
Publicado: (1999)

The instructive role of dendritic cells on T-cell responses
por: Sallusto, Federica, et al.
Publicado: (2002)

Human B cell memory
por: Lanzavecchia, Antonio, et al.
Publicado: (2009)

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
por: Low, Jun Siong, et al.
Publicado: (2022)

Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA
por: Barfod, Lea, et al.
Publicado: (2007)

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
por: Gastaldi, Matteo, et al.
Publicado: (2023)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4(+) T Cells
por: Geginat, Jens, et al.
Publicado: (2001)

Human monoclonal antibodies by immortalization of memory B cells
por: Lanzavecchia, Antonio, et al.
Publicado: (2007)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity
por: Garofalo, Maura, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u6clo0mgie2g1oo2ak5l48opmt